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OBJECTIVES To create a valid, sensitive, disease-specific health status measure for patients with congestive
heart failure (CHF).
BACKGROUND Quantifying health status is becoming increasingly important for CHF. The Kansas City
Cardiomyopathy Questionnaire (KCCQ) is a new, self-administered, 23-item questionnaire
that quantifies physical limitations, symptoms, self-efficacy, social interference and quality of
life.
METHODS To establish the performance characteristics of the KCCQ, two distinct patient cohorts were
recruited: 70 stable and 59 decompensated CHF patients with ejection fractions of ,40.
Upon entry into the study, patients were administered the KCCQ, the Minnesota Living
with Heart Failure Questionnaire and the Short Form-36 (SF-36). Questionnaires were
repeated three months later.
RESULTS Convergent validity of each KCCQ domain was documented by comparison with available
criterion standards (r 5 0.46 to 0.74; p , 0.001 for all). Among those with stable CHF who
remained stable by predefined criteria (n 5 39), minimal changes in KCCQ domains were
detected over three months of observation (mean change 5 0.8 to 4.0 points, p 5 NS for all).
In contrast, large changes in score were observed among patients whose decompensated CHF
improved three months later (n 5 39; mean change 5 15.4 to 40.4 points, p , 0.01 for all).
The sensitivity of the KCCQ was substantially greater than that of the Minnesota Living with
Heart Failure and the SF-36 questionnaires.
CONCLUSIONS The KCCQ is a valid, reliable and responsive health status measure for patients with CHF
and may serve as a clinically meaningful outcome in cardiovascular research, patient
management and quality assessment. (J Am Coll Cardiol 2000;35:1245–55) © 2000 by the
American College of Cardiology
Congestive heart failure (CHF) is a common clinical syn-
drome with an enormous impact on the prognosis and
lifestyle of patients. Furthermore, it is a chronic condition
without a “cure.” The two primary goals of its management
are preventing further disease progression (mortality, hos-
pitalizations and deterioration of left ventricular function)
and alleviating patient suffering. Quantifying this latter
treatment goal requires the use of a health-related quality of
life (HRQoL) instrument. In 1994, the Agency for Health
Care Policy and Research published clinical practice guide-
lines recommending that providers routinely evaluate pa-
tients’ HRQoL and use their assessment to modify and
guide patient care (1). These guidelines also called for
further research to develop better mechanisms of quantify-
ing HRQoL.
Health-related quality of life instruments may be either
generic measures of health status or disease-specific.
Disease-specific measures quantify more clinically relevant
domains than generic health status measures and are often
more sensitive to clinical change (2,3). Currently, there is no
standardized, comprehensive, universally accepted disease-
specific HRQoL instrument for CHF. Traditionally, a
physician would use the New York Heart Association
(NYHA) classification to assess functional status (a combi-
nation of physical limitations and symptoms). Although
simple, this system is subject to interobserver variability,
captures only a limited range of health status and is applied
from a physician’s perspective instead of the patient’s. Other
available disease-specific HRQoL instruments for CHF,
such as the Minnesota Living with Heart Failure Question-
naire (4) (LiHFe) or the Chronic Heart Failure Question-
naire (5), are limited in one or more of the following: their
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lack of responsiveness to clinical change (6–8), the range of
clinical domains that they quantify, their mode of admin-
istration or their clinical interpretability. Given the breadth
and complexity of quality of life (QoL) as it may be
impacted upon by CHF, there is a need for improved
instruments that overcome these deficiencies (1).
The Kansas City Cardiomyopathy Questionnaire
(KCCQ) is a new, self-administered, 23-item questionnaire
developed to provide a better description of HRQoL in
patients with CHF. It quantifies, in a disease-specific
fashion, physical limitation, symptoms (frequency, severity
and recent change over time), QoL, social interference and
self-efficacy. Before being used, an HRQoL instrument
must be rigorously evaluated and demonstrated to be valid
(measure what it intends to), reliable (reproducible over
time in stable patients) and responsive to clinical change.
This report documents the development of the KCCQ, its
validity, its reliability and its responsiveness.
METHODS
Development and design of the KCCQ. The KCCQ
(Appendix 1) was developed after a thorough review of the
medical literature, an examination of currently available
HRQoL instruments and focus groups with patients and
CHF specialists. These efforts identified the following
clinically relevant domains: physical limitations (question 1),
symptoms (frequency [questions 3, 5, 7 and 9], severity
[questions 4, 6 and 8] and change over time [question 2]),
self-efficacy and knowledge (questions 11, 12), social inter-
ference (question 16) and QoL (questions 13–15). The
design and testing of the KCCQ is principally modeled after
the approach used to develop the Seattle Angina Question-
naire (9). The last item of the QoL domain (question 15)
was adapted from the Mental Health Inventory of the
SF-36 because it is a marker of depression (10), an impor-
tant prognostic variable in cardiovascular disease (11–13).
Questions were carefully formatted for gender neutrality,
clarity, interpretability and subsequent foreign language
translations (14). Responses were arrayed on an adjectival
(Likert) scale with clinically meaningful gradations between
categories. A two-week time frame was selected to allow
patients to integrate a representative period of their recent
functioning into their responses. The KCCQ is self-
administered and requires, on average, 4–6 min to com-
plete. It is scored by assigning each response an ordinal
value, beginning with 1 for the response that implies the
lowest level of functioning and summing items within each
domain. Missing values within each domain are assigned
the average of the answered items within that same domain.
Scale scores are transformed to a 0 to 100 range by
subtracting the lowest possible scale score, dividing by the
range of the scale and multiplying by 100. To facilitate
interpretability, two summary scores were developed. Com-
bining the physical limitation and symptom domains (ex-
cluding symptom stability) forms a functional status score.
A clinical summary score can be calculated by combining
the functional status with the QoL and social limitation
domains.
Study design. Instrument selection. To place the KCCQ in
the context of alternative methods of quantifying health
status, two other instruments were administered. The most
commonly used generic health status measure is the RAND
Short Form-36 (SF-36) (15). It was scored according to the
RAND criteria with each domain being transformed to a
0–100 scale where higher scores indicated better health
(16). The LiHFe was also administered throughout these
investigations because it is the most commonly employed
disease-specific health status measure for CHF. To facilitate
comparison of the LiHFe with the other instruments, its
scores were reversed from the usual scoring scheme and
were transformed to a 0–100 scale where higher scores
indicate more favorable states. These mathematical manip-
ulations simplify comparisons between instruments without
altering the performance characteristics of the question-
naire.
Patient selection. To confirm the KCCQ’s validity, reli-
ability and responsiveness, two distinct patient cohorts were
recruited, and multiple analyses were planned and con-
ducted (Table 1). All patients had a clinical diagnosis of
CHF and a documented ejection fraction (EF) of ,40%.
Determination of EF could have been by nuclear imaging
techniques, echocardiogram or left ventriculogram. For
purposes of these studies, the most recent estimation of left
ventricular function was used. Patients were excluded if they
could not read English. The Institutional Review Boards of
the University of Missouri—Kansas City and the Mid-
America Heart Institute approved all aspects of these
studies.
Reliability cohort. This cohort was assembled to demon-
strate the instrument’s test-retest reliability. It was therefore
essential to include patients who would remain stable
throughout the period of observation. Requirements for
stability upon entry included that over the prior two months
there were: 1) no hospitalizations, 2) no change in CHF
medications, and 3) a physician’s assessment of stability.
Patients were enrolled from the outpatient cardiology clinics
of Truman Medical Center and the Mid-America Heart
Abbreviations and Acronyms
CHF 5 congestive heart failure
EF 5 ejection fraction
HRQoL 5 health-related quality of life
KCCQ 5 Kansas City Cardiomyopathy Questionnaire
LiHFe 5 Minnesota Living with Heart Failure
Questionnaire
NYHA 5 New York Heart Association
QoL 5 quality of life
SF-36 5 Short Form 36
6 MWT 5 6 minute walk test
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Institute, Kansas City, Missouri, between September 1997
and April 1998.
Upon entry into the study, patients were administered the
KCCQ, the LiHFe and the SF-36 as well as a 6-min walk
test (6 MWT), a validated measure of physical function in
patients with CHF (17). Patients were telephoned three
months later by a cardiologist who, blinded to initial and
follow-up questionnaire responses, determined their
NYHA class. After this assessment, patients were mailed
the KCCQ, the LiHFe and the SF-36. Patients failing to
return the questionnaires were again contacted by telephone
and encouraged to participate. Questionnaires were not
administered by telephone. Patients who reported a signif-
icant change in their symptoms, required hospitalization or
had had their CHF medicines altered during the period of
observation were excluded from the reliability analyses but
retained for purposes of questionnaire validation.
Responsiveness cohort. A second cohort of patients was
assembled to demonstrate the instrument’s responsiveness.
As opposed to the reliability cohort in whom patients were
selected for clinically stability, this cohort was selected to
capture patients whose clinical status was expected to
change. It was hypothesized that patients admitted to the
hospital with decompensated CHF would be clinically
improved when surveyed three months later. Patients ad-
mitted with CHF exacerbations between September 1997
and April 1998 were recruited for the study. An inability to
read English was the only exclusion criterion. On admis-
sion, patients were assigned a NYHA classification and
asked to complete the KCCQ, the LiHFe and the SF-36.
Three months later a cardiologist, blinded to questionnaire
responses, telephoned patients and determined their NYHA
functional classification. After this assessment, patients were
mailed the KCCQ, the LiHFe and the SF-36. Patients
failing to return the questionnaires were again contacted by
telephone and encouraged to participate, but questionnaires
were not administered by telephone. Per study protocol,
patients who died, underwent heart transplantation or who
were readmitted to the hospital were determined not to have
improved over the period of observation and were excluded
from the responsiveness analyses. Their baseline informa-
tion was retained for instrument validation.
STATISTICAL ANALYSES
Determining questionnaire reliability. Internal consis-
tency was determined using Cronbach’s alpha. This statistic
(range 0–1) reflects the “cohesiveness” of different items
within a single domain. To evaluate the test-retest reliabil-
ity, or reproducibility, of the instruments, paired t tests were
used to analyze the three-month change in scores among
patients retained in the reliability cohort.
Determining questionnaire responsiveness. The respon-
siveness of questionnaires to clinical change was quantified
using paired t tests among patients retained in the respon-
siveness cohort. A responsiveness statistic was also used to
compare the relative sensitivity to clinical change of the
instruments used in these studies (18). This statistic divides
the observed change in patients recovering from a CHF
exacerbation (the “signal” of clinical improvement) by the
standard deviation of change in stable patients (the “noise”
of random variation). The higher the responsiveness statis-
Table 1. Study Designs
Study and Patients Reference Measure Analysis
Reliability Study
Cohort with stable CHF Three-month change in KCCQ scores Paired t test
Responsiveness Study
Cohort with initially decompensated CHF Three-month change in KCCQ scores Paired t test; Guyatt’s
responsiveness statistic
Validation of KCCQ Domains
Physical limitation Distance covered in a 6 minute walk
test, NYHA class, SF-36 and
LiHFe physical limitation domains
Correlation
Symptom stability Difference in scores between stable
and decompensated patients
Two-sample, independent t test
Symptoms NYHA class Correlation
Self-efficacy Difference in scores between stable
and decompensated patients
Two-sample, independent t test
Social limitation NYHA class, SF-36 social scale Correlation
Quality of life SF-36 general health scale, NYHA Correlation
KCCQ functional status NYHA class, end point of survival or
hospitalization
Correlation, t test
KCCQ clinical summary NYHA class, end point of survival or
hospitalization
Correlation, t test
CHF 5 congestive heart failure; KCCQ 5 Kansas City Cardiomyopathy Questionnaire; LiHFe 5 Minnesota Living with Heart Failure Questionnaire; NYHA 5 New York
Heart Association classification; and SF-36 5 Short Form-36.
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tic, the greater the sensitivity of the instrument in detecting
clinical change. Although this statistic ideally uses the
minimal clinically important difference in scores as the
numerator, this value is not currently known for the KCCQ.
Nevertheless, it provides a useful metric with which to
compare the sensitivities of different instruments.
Determining the validity of the KCCQ. Because no “gold
standard” for functional status or QoL is available, conver-
gent validity of each domain was sought by comparison with
other measures that quantify similar concepts (19). Baseline
data from both the reliability and responsiveness cohorts
were used to assess the validity of each KCCQ domain.
Validation of the physical limitation domain. The physical
limitation domain was validated against walking distances
during a 6 MWT performed at baseline among patients in
the reliability cohort (17). The rationale for this comparison
lies in the recognition that patients reporting more physical
limitation on the KCCQ would be expected to walk a
shorter distance in 6 min than patients reporting less
physical limitation. Distance traveled on the 6 MWT was,
therefore, correlated with the physical limitation domain of
the KCCQ. To further demonstrate the convergent validity
of the KCCQ’s physical limitation domain, it was compared
with the NYHA classification and the physical limitation
domains of the SF-36 and the LiHFe, other accepted
measures of physical limitation.
Validation of the symptom domain. Because the NYHA
quantifies both symptoms and physical limitations, it was
hypothesized that a scale accurately quantifying symptoms
should have worse scores for higher NYHA classes. An
analysis of variance with a test for linear trend was per-
formed to compare baseline KCCQ symptom scores with
NYHA classification.
Validation of symptom stability domain. Unlike other do-
mains of the KCCQ that quantify, in a cross-sectional
fashion, patients’ health status, this domain evaluates recent
changes in symptoms over time. It was hypothesized that
stable patients should have scores near 50 (indicating no
change in symptoms over the past month) and that patients
admitted to the hospital for decompensated CHF should
have scores below 50, indicating recent worsening of their
symptoms. The baseline mean score of this question among
stable patients seen in the reliability cohort was compared
with patients from the responsiveness cohort admitted to
the hospital with decompensated CHF.
Validation of the self-efficacy domain. This domain cap-
tures information that is relatively unique, and we are
unaware of any other validated measure that quantitatively
summarizes this information. We hypothesized that pa-
tients admitted to the hospital for a CHF exacerbation
would be less knowledgeable about how to manage their
disease than stable outpatients. A two-sided, independent t
test was used to compare the baseline scores of patients in
the reliability and responsiveness cohorts.
Validation of the QoL domain. The QoL domain seeks to
quantify how patients’ disease impacts their overall QoL.
This scale was correlated with the general health perception
scale of the SF-36. As a post-hoc analysis, a comparison of
these two domains with the NYHA classification was done
to determine which was more accurately reflecting the QoL
in patients with CHF. This comparison is predicated on the
assumption that the NYHA classification also correlates
with QoL.
Validation of the social limitation domain. This domain
was correlated with the social functioning domain of the
SF-36, a generic health status measure quantifying a similar
concept, and the NYHA classification.
Validation of the KCCQ functional status score. We hy-
pothesized that the functional status scores would be sub-
stantially different among patients in different NYHA
classifications. The rationale for this expectation lies in the
recognition that this score represents a synthesis of the
physical and symptom limitations due to CHF, the very
same considerations taken into account by physicians as they
assign NYHA classifications. An analysis of variance with a
test for linear trend was used to compare baseline functional
status scores with NYHA classifications. In addition, pa-
tients who were initially enrolled in these investigations and
subsequently died or were hospitalized would be expected to
have worse health status at the time of their initial assess-
ment than those with event-free survival. An independent t
test of baseline functional status scores was performed
between those who died or were hospitalized and those with
event-free survival.
Validation of the KCCQ clinical summary score. In addition
to the components included in the functional status score,
this score also includes the social limitation and QoL
domains of the KCCQ. This score was validated in the
same fashion as the KCCQ functional status score by
comparisons with NYHA class and by a t test of baseline
scores among those with and without an event-free survival
during follow-up procedure.
RESULTS
Summary of study cohorts. Reliability cohort. Seventy pa-
tients were identified as having been stable and were
recruited into the reliability cohort. Over the next three
months, 31 patients were removed from the cohort for the
following reasons: 17 patients required hospitalization or
had had their medications changed, 9 underwent heart
transplantation or died and 5 did not return their follow-up
questionnaires. Patients without follow-up questionnaires
for analysis were not significantly different from those who
did participate in follow-up with respect to their baseline
characteristics (sociodemographic, clinical or health status).
The mean age of the 39 stable patients available for the
reliability analyses was 64 years; 69% were men, and the
mean NYHA was 2.0 6 0.59.
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Responsiveness cohort. Fifty-nine patients were initially
recruited into the responsiveness cohort. Twenty patients
were removed from the cohort for the following reasons:
nine patients died or required heart transplantation, three
were readmitted with CHF, three were lost to follow-up,
and five failed to return the questionnaires. Patients without
follow-up questionnaires for analysis were not significantly
different in terms of any baseline characteristics (sociode-
mographic, clinical or health status) except that those
without follow-up were younger than those with follow-up
(57.2 vs. 67.4, p 5 0.036). Thirty-nine patients returned the
final three-month questionnaires: 62% were men; the mean
age was 68 years, and the mean baseline NYHA classifica-
tion was 3.3 6 0.46.
Validation analyses. For the validation analyses compar-
ing the KCCQ with reference standards, all 129 patients
with available baseline data were included. The combined
cohort had a mean age of 64.3 years, a mean EF of 23.5%
and 70% were men. All NYHA classes were represented
(I 5 7; II 5 41; III 5 61; IV 5 20).
Reliability of the KCCQ. Table 2 summarizes the internal
consistency of each KCCQ domain. Only the self-efficacy
domain failed to attain a high internal consistency. The
lower Cronbach’s alpha for this domain reflects that it is
composed of only two questions acquiring slightly different
pieces of information.
Table 3 summarizes the mean scores at baseline and
follow-up (mean duration of follow-up 5 3.3 months)
among the 39 patients retained in the reliability cohort. The
mean changes of 0.8 to 4.0 points on a 100-point scale over
three months of observation were small and not statistically
significant. Similar reproducibility was noted for both the
LiHFe and the NYHA. Only the SF-36’s social limitation
scale changed significantly.
Responsiveness of the KCCQ. In contrast to the stability
of KCCQ scores observed among members of the reliability
cohort, dramatic changes were seen in the responsiveness
cohort. The mean baseline, three-month and change in
scores are shown in Table 4. All scales of the KCCQ were
substantially more sensitive to the important clinical change
experienced by this cohort, namely recovering from a severe
exacerbation of CHF, than either the LiHFe or the SF-36.
Whereas the KCCQ scores improved by 15.4 to 40.4
Table 2. Internal Consistency of the KCCQ
KCHFQ Domain
Cronbach’s
Alpha
Physical limitation 0.90
Symptoms 0.88
Quality of life 0.78
Social limitation 0.86
Self-efficacy 0.62
KCCQ functional status 0.93
KCCQ clinical summary 0.95
Table 3. Mean Three-Month Change in Health Status Scores Among Patients (n 5 39) in the
Reliability Cohort
Questionnaire and Scale
Baseline
Mean Value
Three-Month
Mean Value
Mean
Difference p Value
KCCQ
Physical limitation 64.4 65.2 0.8 0.72
Symptoms 76.6 73.1 23.5 0.06
Symptom stability 54.3 55.5 1.2 0.61
Social limitation 59.2 57.4 21.8 0.68
Self-efficacy 83.3 85.5 2.2 0.46
Quality of life 64.5 60.5 24.0 0.29
KCCQ functional status 70.5 69.1 21.4 0.42
KCCQ clinical summary 66.2 64.1 22.1 0.36
LiHFe
Physical function 52.9 49.6 23.3 0.35
Emotional scale 69.7 68.9 20.8 0.78
Total LiHFe score 62.1 59.0 23.1 0.20
SF-36
Physical function 49.7 46.5 23.2 0.19
Bodily pain 76.8 72.1 24.7 0.29
General health 47.8 44.7 23.1 0.20
Mental health 71.6 69.3 22.3 0.28
Vitality 46.9 43.0 23.9 0.20
Role—emotional 60.5 55.3 25.2 0.51
Social function 76.9 65.4 211.5 0.008
Role—physical 52.9 49.6 23.3 0.11
NYHA 2.08 2.05 20.03 0.57
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points, the largest change in either the LiHFe or the SF-36
was 11.3 points. This increased sensitivity to clinical change,
over the random variation seen in stable patients, is sum-
marized by the responsiveness statistics. For example, the
KCCQ physical limitation scale’s responsiveness statistic of
1.48 is almost three times larger than the corresponding
domains of the LiHFe (responsiveness statistic 5 0.52) and
SF-36 (responsiveness statistic 5 0.59). The KCCQ Symp-
tom scale has the largest “signal-to-noise” ratio (responsive-
ness statistic 5 3.19) of any instrument used in these
studies. The increased sensitivity of the KCCQ domains to
clinical change, as compared with their baseline variability
in stable patients, should greatly increase the KCCQ’s
ability to detect important clinical changes in future clinical
trials.
Validation of the KCCQ. Physical limitation domain. Ta-
ble 5 outlines the results supporting the validity of the
KCCQ physical limitation domain. The KCCQ physical
limitation score had a high Spearman’s correlation coeffi-
cient with NYHA classification (20.65, p , 0.001) and
other measures of physical limitation. Among the 49 mem-
bers of the reliability cohort who underwent the 6 MWT
(mean age 62 years; 69% male; mean EF 5 25%; NYHA
I 5 5, NYHA II 5 28 and NYHA III 5 16), the KCCQ
correlated significantly with distance walked (0.48, p , 0.001).
Symptom stability score. On this scale, lower scores indi-
cate worsening CHF symptoms, and higher scores represent
symptom improvement over the preceding two weeks. A
score of 50 indicates no change in symptoms. The mean
KCCQ symptom stability scores were significantly lower
Table 4. Mean Three-Month Change in Questionnaire Scores Among Patients Initially Admitted to the Hospital With CHF
(n 5 39)
Questionnaire
and Scale
Baseline
Mean Value
Three-Month
Mean Value
Mean
Difference
p
Value
Responsiveness
Statistic
KCCQ
Physical limitation 34.7 55.7 21.0 ,0.001 1.48
Symptoms 31.3 67.4 36.1 ,0.001 3.19
Symptom stability 24.1 64.5 40.4 ,0.001 2.62
Social limitation 31.1 47.9 16.8 0.004 0.62
Self-efficacy 67.6 83.0 15.4 ,0.001 0.83
Quality of life 30.5 50.6 20.1 ,0.001 0.86
KCCQ functional status 33.0 61.5 28.5 ,0.001 2.77
KCCQ clinical summary 31.8 56.1 24.3 ,0.001 1.74
LiHFe
Physical function 32.5 43.8 11.3 0.02 0.52
Emotional scale 41.6 52.1 10.5 0.06 0.64
Total LiHFe score 38.1 49.0 10.9 0.01 0.73
SF-36
Physical function 26.8 35.5 8.7 0.02 0.59
Bodily pain 60.4 58.6 21.8 0.73 0.07
General health 37.2 37.4 0.2 0.98 0.01
Mental health 62.9 67.4 4.5 0.18 0.35
Vitality 27.3 38.2 10.9 0.02 0.60
Role—emotional 34.3 38.4 4.1 0.53 0.08
Social function 49.7 55.4 5.7 0.38 0.22
Role—physical 15.5 19.1 3.6 0.53 0.08
NYHA 3.2 2.4 20.8 ,0.001 2.86
Table 5. Correlation of KCCQ Physical Limitation Scale
Measure
6-min Walk
Test NYHA
SF-36
Physical
Limitation
LiHFe
Physical
KCCQ physical limitation 0.48** 20.65** 0.84** 0.65**
LiHFe physical 0.41* 20.58** 0.72** —
*p , 0.01; **p , 0.001.
KCCQ 5 Kansas City Cardiomyopathy Questionnaire; LiHFe 5 Minnesota Living with Heart Failure; NYHA 5 New
York Heart Association; SF-36 5 Short Form-36.
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among patients admitted to the hospital (n 5 59) than
among those who were stable (n 5 70) (25.8 vs. 53.8, p ,
0.0001).
Symptom scale. This scale summarizes the results of the
symptom frequency and symptom severity domains of the
KCCQ. Figure 1A summarizes the mean scores among
patients in different NYHA classes. An analysis of variance
revealed statistical differences (F 5 51.3, p , 0.001) that
were largely explained by a linear trend (R2 5 0.51; F 5
142.2, p , 0.001). Similar relationships were observed
between the individual components of the symptom score
(frequency and severity) and NYHA classification when
analyzed individually.
QoL domain. A significant correlation (r 5 0.45, p ,
0.001) was seen between the KCCQ QoL domain and the
general health perception scale of the SF-36. Since the
correlation with the SF-36 scales was only modest, it was
unclear which of the scales was more accurately capturing
QoL among patients with CHF. A much higher correlation
with NYHA classification was seen with the KCCQ (r 5
20.64, p , 0.001) than with the SF-36 general health scale
(r 5 20.46, p 5 0.02). The KCCQ QoL domain also
correlated significantly with the emotional domain of the
LiHFe (r 5 0.62, p , 0.001).
Social limitation domain. The KCCQ social limitation
domain was significantly correlated with the SF-36 social
limitation scale (r 5 0.62, p , 0.001) and with NYHA class
(r 5 20.57, p , 0.001).
Self-efficacy domain. No adequate criterion standard is
available for this domain, and acceptance of this domain
could be made on its “face” validity, reliability and respon-
siveness. To further justify the validity of these items, a
comparison was made between the self-efficacy of stable
outpatients with CHF and those who are admitted to the
hospital with decompensated symptoms. Tables 3 and 4
demonstrate that scores were significantly lower among
patients admitted to the hospital than among stable outpa-
tients (67.6 vs. 83.5, p , 0.0001). Among patients in the
responsiveness cohort who improved, self-efficacy scores
also improved significantly at follow-up (67.6 vs. 83.0, p ,
0.001). This may be due to patients’ better understanding of
how to manage their disease as a result of the educational
processes that occur during hospital admission at the two
recruiting centers.
KCCQ functional status score. As shown in Figure 1B,
mean scores on this scale were different among patients in
different NYHA classifications (F 5 52.3, p , 0.001). Not
only was this scale closely correlated with NYHA classifi-
cation (test for linear trend F 5 153 and R2 5 0.55; p ,
0.001), but baseline scores were also associated with subse-
quent death or hospitalization during follow-up procedures.
Over the course of the study, 11 patients died and 13
patients required hospitalization. The baseline KCCQ
functional status score was significantly lower among pa-
tients dying or requiring rehospitalization during the
follow-up period than among those with event-free survival
(35.1 vs. 55.3, p , 0.001).
KCCQ clinical summary score. This scale includes the
functional status score as well as the KCCQ QoL and social
limitation scores. Like the functional status score, the
functional status score correlated with NYHA class (Fig.
1C, overall analysis of variance F statistic 5 41.9, p ,
0.001; test for linear trend F 5 156.8, p , 0.001; R2 5
0.55). There also was a significantly lower baseline score
among patients who died or were rehospitalized than those
with event-free survival (34.1 vs. 52.1, p 5 0.001).
DISCUSSION
In an era of rapidly expanding therapies for CHF, there is a
need for robust mechanisms of quantifying the impact of
new treatments on patients, their survival, their symptoms
and their QoL. In addition, payers, practitioners and regu-
latory agencies are increasingly relying upon patient-
centered outcomes to monitor and improve quality of care.
To meet these needs, we have developed a new, self-
administered, disease-specific health status measure for
patients with CHF.
This report details the development, validity, reliability
and reproducibility of the KCCQ. In support of its validity,
Figure 1. A. Mean KCCQ symptom score by NYHA classifica-
tion B. Mean KCCQ Functional Status Score by NYHA classi-
fication C. Mean KCCQ Clinical Summary Score by NYHA
classification
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predictable and significant relationships with the best avail-
able criterion standards were demonstrated for each indi-
vidual domain of the KCCQ. Among a cohort of stable
patients with CHF, no significant changes were detected
over a three-month period of observation. In contrast, large
changes were observed among a separate cohort of patients
recovering from an admission for decompensated heart
failure.
The KCCQ offers several advantages over the LiHFe,
another disease specific HRQoL instrument for CHF. The
KCCQ not only captures physical limitations, but also
independently quantifies symptoms (frequency, severity and
stability), social limitations, patients’ sense of self-efficacy
and QoL. Although both the KCCQ and LiHFe appear to
be valid and reliable, the KCCQ is much more sensitive to
clinical change than the LiHFe. The lack of sensitivity to
clinical change may, in part, explain why some clinical trials
have failed to demonstrate important benefits in QoL
despite improvements in other clinical markers (6–8). The
increased sensitivity of the KCCQ was also apparent when
compared with the SF-36. This is consistent with the
growing evidence of generic health status instruments’
limited responsiveness to treatment effects (3,20,21).
The Chronic Heart Failure Questionnaire developed by
Gordon Guyatt (5) is a reliable and responsive measure for
patients with CHF (22). However, its usefulness has been
limited by the complexity of its administration.
Study limitations. Validating the KCCQ was complicated
by the absence of appropriate reference standards for the
various domains. Although we recognize the limitations of
our comparison standards, we feel these were the best
options available. A second concern is the loss to follow-up
of four patients (3%) and the failure of nine patients (7%) to
return follow-up questionnaires. Although it is unknown
how their responses might have altered our findings, it
seems unlikely that they would significantly alter our con-
clusions. Furthermore, future users of our instrument are
likely to have a portion of their subjects similarly fail to
provide follow-up, and our results are likely to be general-
izable to those of their patients that do provide follow-up
responses.
Finally, we recognize that we have examined this instru-
ment in a relatively small number of patients. Further work
in other populations, including those with diastolic rather
than systolic dysfunction, will better define the generaliz-
ability of our findings. In addition, we have not yet
determined the minimal clinically important difference in
KCCQ scores. More experience in different clinical settings
should further illuminate this information.
Potential applications of the KCCQ. It is hoped that the
KCCQ will serve as an end point in clinical trials and be
useful in disease management or quality assessment/
improvement programs. In addition to mortality, investiga-
tors often rely on physiologic variables, such as left ventric-
ular EF or plasma norepinephrine levels as surrogate end
points. However, surrogate end points may not always be as
useful as expected (23). The KCCQ can directly quantify
clinical benefits from patients’ perspectives.
Conclusions. The benefit and importance of functional
status assessment and patient outcomes data has become
increasingly recognized. The KCCQ is a valid, reliable and
responsive HRQoL instrument for patients with CHF and
may serve as a clinically meaningful outcome measure in
cardiovascular research, patient management and quality
assessment.
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APPENDIX
THE KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE:
The following questions refer to your heart failure and how it may affect your life. Please read and complete the following
questions. There are no right or wrong answers. Please mark the answer that best applies to you.
1. Heart failure affects different people in different ways. Some feel shortness of breath while others feel fatigue. Please indicate how
much you are limited by heart failure (shortness of breath or fatigue) in your ability to do the following activities over the past 2
weeks.
Place an X in one box on each line
Activity Extremely
Limited
Quite a bit
Limited
Moderately
Limited
Slightly
Limited
Not at all
Limited
Limited for other reasons
or did not do the activity
Dressing yourself o o o o o o
Showering/Bathing o o o o o o
Walking 1 block on
level ground
o o o o o o
Doing yardwork,
housework or
carrying groceries
o o o o o o
Climbing a flight of
stairs without
stopping
o o o o o o
Hurrying or jogging
(as if to catch a bus)
o o o o o o
2. Compared with 2 weeks ago, have your symptoms of heart failure (shortness of breath, fatigue or ankle swelling) changed?
My symptoms of heart failure have become . . .
Much worse Slightly worse Not changed Slightly better Much better I’ve had no symptoms
over the last 2 weeks
o o o o o o
3. Over the past 2 weeks, how many times did you have swelling in your feet, ankles or legs when you woke up in the morning?
Every morning 3 or more times
a week, but not
every day
1–2 times a
week
Less than once a
week
Never over the
past 2 weeks
o o o o o
4. Over the past 2 weeks, how much has swelling in your feet, ankles or legs bothered you?
It has been . . .
Extremely
bothersome
Quite a bit
bothersome
Moderately
bothersome
Slightly
bothersome
Not at all
bothersome
I’ve had no swelling
o o o o o o
5. Over the past 2 weeks, on average, how many times has fatigue limited your ability to do what you want?
All of the time Several times
per day
At least once a
day
3 or more times
per week but not
every day
1–2 times per
week
Less than once a
week
Never over the past
2 weeks
o o o o o o o
6. Over the past 2 weeks, how much has your fatigue bothered you?
It has been . . .
Extremely
bothersome
Quite a bit
bothersome
Moderately
bothersome
Slightly
bothersome
Not at all
bothersome
I’ve had no fatigue
o o o o o o
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7. Over the past 2 weeks, on average, how many times has shortness of breath limited your ability to do what you wanted?
All of the time Several times
per day
At least once a
day
3 or more times
per week but not
every day
1–2 times per
week
Less than once a
week
Never over the past
2 weeks
o o o o o o o
8. Over the past 2 weeks, how much has your shortness of breath bothered you?
It has been . . .
Extremely
bothersome
Quite a bit
bothersome
Moderately
bothersome
Slightly
bothersome
Not at all
bothersome
I’ve had no shortness
of breath
o o o o o o
9. Over the past 2 weeks, on average, how many times have you been forced to sleep sitting up in a chair or with at least 3 pillows
to prop you up because of shortness of breath?
Every night 3 or more times
a week, but not
every day
1–2 times a
week
Less than once a
week
Never over the
past 2 weeks
o o o o o
10. Heart failure symptoms can worsen for a number of reasons. How sure are you that you know what to do, or whom to call, if
your heart failure gets worse?
Not at all sure Not very sure Somewhat sure Mostly sure Completely sure
o o o o o
11. How well do you understand what things you are able to do to keep your heart failure symptoms from getting worse? (for
example, weighing yourself, eating a low salt diet, etc.)
Do not
understand
at all
Do not
understand
very well
Somewhat
understand
Mostly
understand
Completely
understand
o o o o o
12. Over the past 2 weeks, how much has your heart failure limited your enjoyment of life?
It has extremely
limited my
enjoyment of
life
It has limited my
enjoyment of life
quite a bit
It has
moderately
limited my
enjoyment of life
It has slightly
limited my
enjoyment of life
It has not
limited my
enjoyment of life
at all
o o o o o
13. If you had to spend the rest of your life with your heart failure the way it is right now, how would you feel about this?
Not at all
satisfied
Mostly
dissatisfied
Somewhat
satisfied
Mostly satisfied Completely
satisfied
o o o o o
14. Over the past 2 weeks, how often have you felt discouraged or down in the dumps because of your heart failure?
I felt that way
all of the time
I felt that way
most of the time
I occasionally
felt that way
I rarely felt that
way
I never felt that
way
o o o o o
15. How much does your heart failure affect your lifestyle? Please indicate how your heart failure may have limited your
participation in the following activities over the past 2 weeks.
Please place an X in one box on each line
Activity Severely
limited
Limited
quite a bit
Moderately
limited
Slightly
limited
Did not
limit at all
Does not apply or did
not do for other reasons
Hobbies, recreational activities o o o o o o
Working or doing household chores o o o o o o
Visiting family or friends
out of your home
o o o o o o
Intimate relationships with loved ones o o o o o o
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